{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T15:50:28Z","timestamp":1794498628902,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Knight Inititiative for Brain Resilience"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00435, PI22\/00611, INT19\/00016, INT23\/00048"],"award-info":[{"award-number":["PI18\/00435, PI22\/00611, INT19\/00016, INT23\/00048"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Centralized Repository for Alzheimer's Disease and Related Dementias","award":["P50 AG047366"],"award-info":[{"award-number":["P50 AG047366"]}]},{"name":"National Alzheimer\u2019s Coordinating Center","award":["P30 AG066515"],"award-info":[{"award-number":["P30 AG066515"]}],"id":[{"id":"https:\/\/ror.org\/03qm4p447","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AG058859"],"award-info":[{"award-number":["R21AG058859"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 NS075097, R01NS115114"],"award-info":[{"award-number":["K23 NS075097, R01NS115114"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["#2023-00356, #2022-01018, #2019-02397"],"award-info":[{"award-number":["#2023-00356, #2022-01018, #2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["No 101053962"],"award-info":[{"award-number":["No 101053962"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["No 101081334"],"award-info":[{"award-number":["No 101081334"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish State Support for Clinical Research","award":["#ALFGBG-71320"],"award-info":[{"award-number":["#ALFGBG-71320"]}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["#201809-2016862"],"award-info":[{"award-number":["#201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AD Strategic Fund and the Alzheimer's Association","award":["#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C"],"award-info":[{"award-number":["#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C"]}],"id":[{"id":"https:\/\/ror.org\/0375f4d26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019599","name":"European Partnership on Metrology","doi-asserted-by":"publisher","award":["#22HLT07"],"award-info":[{"award-number":["#22HLT07"]}],"id":[{"id":"10.13039\/100019599","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Bluefield Project"},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer\u2019s Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021720","name":"Olav Thon Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007436","name":"Erling-Persson Family Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Familjen R\u00f6nstr\u00f6ms Stiftelse"},{"name":"Familjen Beiglers Stiftelse"},{"name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor, Hj\u00e4rnfonden, Sweden","award":["#FO2022-0270"],"award-info":[{"award-number":["#FO2022-0270"]}],"id":[{"id":"https:\/\/ror.org\/04fx88130","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["No 860197"],"award-info":[{"award-number":["No 860197"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union Joint Programme \u2013 Neurodegenerative Disease Research","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"https:\/\/ror.org\/0187kwz08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Susan and Charles Berghoff Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01341-8","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:06:00Z","timestamp":1775804760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Plasma phosphorylated tau 217 detects amyloid-\u03b2 in neuronal synuclein disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Alena M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Lorkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Montoliu-Gaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward N.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Rodr\u00edguez-Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Shahid-Besanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Vossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Plastini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vera-Campuzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin H.","family":"Mendiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Kerchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin I.","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Montine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Mormino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Poston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Abdelnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1341_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1341_CR2","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti, C. et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat. Med. 29, 1964\u20131970 (2023).","journal-title":"Nat. Med."},{"key":"1341_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.nbd.2019.02.023","volume":"127","author":"M Shahid","year":"2019","unstructured":"Shahid, M. et al. An increased rate of longitudinal cognitive decline is observed in Parkinson\u2019s disease patients with low CSF A\u00df42 and an APOE \u03b54 allele. Neurobiol. Dis. 127, 278\u2013286 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1341_CR4","doi-asserted-by":"publisher","unstructured":"Ryman S. G., et al. Cognition at each stage of Lewy body disease with co-occurring Alzheimer\u2019s disease pathology. Dugger B, editor. J Alzheimer\u2019s Dis. 2021;80:1243\u201356. https:\/\/doi.org\/10.3233\/JAD-201187.","DOI":"10.3233\/JAD-201187"},{"key":"1341_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102333","volume":"27","author":"C Abdelnour","year":"2020","unstructured":"Abdelnour, C. et al. The combined effect of amyloid-beta and tau biomarkers on brain atrophy in dementia with Lewy bodies. Neuroimage Clin. 27, 102333. https:\/\/doi.org\/10.1016\/j.nicl.2020.102333 (2020).","journal-title":"Neuroimage Clin."},{"key":"1341_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-021-00946-w","volume":"14","author":"C Abdelnour","year":"2022","unstructured":"Abdelnour, C. et al. Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimers Res. Ther. 14, 14 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1341_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214040","volume":"105","author":"D Esteller-Gauxax","year":"2025","unstructured":"Esteller-Gauxax, D. et al. \u03b1-Synuclein seed amplifications assay in a cohort with cognitive impairment: performance and interactions with CSF and plasma biomarkers. Neurology 105, e214040. https:\/\/doi.org\/10.1212\/WNL.0000000000214040 (2025).","journal-title":"Neurology"},{"key":"1341_CR8","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta, Y. et al. Lewy- and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: which is more important? Brain 134, 1493\u20131505 (2011).","journal-title":"Brain"},{"key":"1341_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/mds.26668","volume":"31","author":"C Abdelnour","year":"2016","unstructured":"Abdelnour, C. et al. Alzheimer\u2019s disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. Mov. Disord. 31, 1203\u20131208 (2016).","journal-title":"Mov. Disord."},{"key":"1341_CR10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ana.27003","volume":"96","author":"C Abdelnour","year":"2024","unstructured":"Abdelnour, C. et al. Plasma pTau181 reveals a pathological signature that predicts cognitive outcomes in Lewy Body Disease. Ann. Neurol. 96, 526\u2013538 (2024).","journal-title":"Ann. Neurol."},{"key":"1341_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s007020200027","volume":"109","author":"KA Jellinger","year":"2002","unstructured":"Jellinger, K. A., Seppi, K., Wenning, G. K. & Poewe, W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson\u2019s disease. J. Neural Transm. 109, 329\u2013339 (2002).","journal-title":"J. Neural Transm."},{"key":"1341_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255\u2013263 (2024).","journal-title":"JAMA Neurol."},{"key":"1341_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid beta positivity with further confirmatory testing only in uncertain cases. Nat. Aging 3, 1079\u20131090 (2023).","journal-title":"Nat. Aging"},{"key":"1341_CR14","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1002\/alz.14140","volume":"20","author":"DJ Figdore","year":"2024","unstructured":"Figdore, D. J. et al. Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays. Alzheimers Dement. 20, 6506\u20136516 (2024).","journal-title":"Alzheimers Dement."},{"key":"1341_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","volume":"146","author":"L Yu","year":"2023","unstructured":"Yu, L. et al. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol. 146, 1\u201311 (2023).","journal-title":"Acta Neuropathol."},{"key":"1341_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat. Rev. Neurol. 20, 426\u2013439 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1341_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209418","volume":"102","author":"K Bolsewig","year":"2024","unstructured":"Bolsewig, K. et al. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies. Neurology 102, e209418. https:\/\/doi.org\/10.1212\/WNL.0000000000209418 (2024).","journal-title":"Neurology"},{"key":"1341_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","volume":"79","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez, M. C. et al. Association of Plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol. 79, 32 (2022).","journal-title":"JAMA Neurol."},{"key":"1341_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2022.07.008","volume":"101","author":"PC Donaghy","year":"2022","unstructured":"Donaghy, P. C. et al. The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. Parkinson. Relat. Disord. 101, 111\u2013116 (2022).","journal-title":"Parkinson. Relat. Disord."},{"key":"1341_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13195-024-01502-y","volume":"16","author":"A Vrillon","year":"2024","unstructured":"Vrillon, A. et al. Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies. Alzheimers Res Ther. 16, 146 (2024).","journal-title":"Alzheimers Res Ther."},{"key":"1341_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mds.28370","volume":"36","author":"S Hall","year":"2021","unstructured":"Hall, S. et al. Plasma Phospho-Tau Identifies Alzheimer\u2019s co-pathology in patients with Lewy body disease. Mov. Disord. 36, 767\u2013771 (2021).","journal-title":"Mov. Disord."},{"key":"1341_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41531-022-00384-x","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu, L. et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. NPJ Park Dis. 8, 154 (2022).","journal-title":"NPJ Park Dis."},{"key":"1341_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.parkreldis.2022.05.020","volume":"105","author":"J Pagonabarraga","year":"2022","unstructured":"Pagonabarraga, J. et al. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson\u2019s disease. Park Relat. Disord. 105, 132\u2013138 (2022).","journal-title":"Park Relat. Disord."},{"key":"1341_CR24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/mds.28994","volume":"37","author":"AJ Thomas","year":"2022","unstructured":"Thomas, A. J. et al. A longitudinal study of plasma pTau181 in mild cognitive impairment with Lewy bodies and Alzheimer\u2019s disease. Mov. Disord. 37, 1495\u20131504 (2022).","journal-title":"Mov. Disord."},{"key":"1341_CR25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","volume":"93","author":"L Chouliaras","year":"2022","unstructured":"Chouliaras, L. et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry 93, 651\u2013658 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1341_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","volume":"14","author":"S Baiardi","year":"2022","unstructured":"Baiardi, S. et al. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res. Ther. 14, 153 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1341_CR27","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","volume":"92","author":"D Alcolea","year":"2021","unstructured":"Alcolea, D. et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J. Neurol. Neurosurg. Psychiatry 92, 1206\u20131214 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1341_CR28","volume":"16","author":"RZ Rousset","year":"2024","unstructured":"Rousset, R. Z. et al. Performance of plasma p-tau217 and NfL in an unselected memory clinic setting. Alzheimers Dement Diagn. Assess. Dis. Monit. 16, e70003 (2024).","journal-title":"Alzheimers Dement Diagn. Assess. Dis. Monit."},{"key":"1341_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, e17123 (2023).","journal-title":"EMBO Mol. Med."},{"key":"1341_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","volume":"9","author":"Y Tang","year":"2023","unstructured":"Tang, Y. et al. Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia. NPJ Park Dis. 9, 23 (2023).","journal-title":"NPJ Park Dis."},{"key":"1341_CR31","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/acn3.51768","volume":"10","author":"KAQ Cousins","year":"2023","unstructured":"Cousins, K. A. Q. et al. Plasma GFAP associates with secondary Alzheimer\u2019s pathology in Lewy body disease. Ann. Clin. Transl. Neurol. 10, 802\u2013813 (2023).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1341_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208033","volume":"102","author":"KAQ Cousins","year":"2024","unstructured":"Cousins, K. A. Q. et al. Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson's disease. Neurology 102, e208033 (2024).","journal-title":"Neurology"},{"key":"1341_CR33","doi-asserted-by":"publisher","first-page":"e1038","DOI":"10.1212\/WNL.0000000000005166","volume":"90","author":"DJ Irwin","year":"2018","unstructured":"Irwin, D. J. et al. CSF tau and beta-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology. 90, e1038\u2013e1046 (2018).","journal-title":"Neurology."},{"key":"1341_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/alz.13398","volume":"20","author":"L Jain","year":"2024","unstructured":"Jain, L. et al. ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium. Alzheimer's Dement 20, 549\u2013562 (2024).","journal-title":"Alzheimer's Dement"},{"key":"1341_CR35","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1002\/alz.13799","volume":"20","author":"N Samudra","year":"2024","unstructured":"Samudra, N. et al. Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort. Alzheimer's Dement 20, 3334\u20133341 (2024).","journal-title":"Alzheimer's Dement"},{"key":"1341_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209656","volume":"103","author":"DG Coughlin","year":"2024","unstructured":"Coughlin, D. G. et al. Association of CSF alpha-Synuclein seeding amplification assay results with clinical features of possible and probable dementia with Lewy Bodies. Neurology. 103, e209656 (2024).","journal-title":"Neurology."},{"key":"1341_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3233\/JAD-170274","volume":"59","author":"R Skogseth","year":"2017","unstructured":"Skogseth, R. et al. Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. J. Alzheimers Dis. 59, 1139\u20131152 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"1341_CR38","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016 [cited 2025 Jun 2]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/."},{"key":"1341_CR39","first-page":"1","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea, D. et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's Dement Transl. Res. Clin. Inter. 5, 1 (2019).","journal-title":"Alzheimer's Dement Transl. Res. Clin. Inter."},{"key":"1341_CR40","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimer's Dement. 18, 2269\u20138686 (2022).","journal-title":"Alzheimer's Dement."},{"key":"1341_CR41","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/WCO.0000000000001173","volume":"36","author":"LL Gibson","year":"2023","unstructured":"Gibson, L. L., Abdelnour, C., Chong, J., Ballard, C. & Aarsland, D. Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Curr. Opin. Neurol. 36, 264\u2013275 (2023).","journal-title":"Curr. Opin. Neurol."},{"key":"1341_CR42","doi-asserted-by":"publisher","unstructured":"Abdelnour C., Gibson L. L., Batzu L., Aarsland D. How to advance the pharmacological management of cognitive impairment in Parkinson\u2019s disease. J. Park Dis. 2025;0. https:\/\/doi.org\/10.1177\/1877718x251315645.","DOI":"10.1177\/1877718x251315645"},{"key":"1341_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.14283\/jpad.2024.36","volume":"11","author":"ND Prins","year":"2024","unstructured":"Prins, N. D. et al. Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies. J. Prev. Alzheimer's Dis. 11, 549\u2013557 (2024).","journal-title":"J. Prev. Alzheimer's Dis."},{"key":"1341_CR44","doi-asserted-by":"publisher","first-page":"e1708","DOI":"10.1212\/WNL.0000000000207755","volume":"101","author":"JJ Alam","year":"2023","unstructured":"Alam, J. J. et al. Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies. Neurology 101, e1708\u2013e1717 (2023).","journal-title":"Neurology"},{"key":"1341_CR45","first-page":"1155","volume":"12","author":"SID Weinshel","year":"2022","unstructured":"Weinshel, S. I. D. Appropriateness of applying cerebrospinal fluid biomarker cutoffs from Alzheimer\u2019s disease to Parkinson\u2019s Disease. J. Park Dis. 12, 1155\u20131167 (2022).","journal-title":"J. Park Dis."},{"key":"1341_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70562","volume":"21","author":"L Montoliu-Gaya","year":"2025","unstructured":"Montoliu-Gaya, L. et al. Plasma tau biomarkers are distinctly associated with tau tangles and decreased with Lewy body pathology. Alzheimer's Dement 21, e70562 (2025).","journal-title":"Alzheimer's Dement"},{"key":"1341_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66090-x","volume":"10","author":"C Delaby","year":"2020","unstructured":"Delaby, C. et al. Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci. Rep. 10, 9161 (2020).","journal-title":"Sci. Rep."},{"key":"1341_CR48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"1341_CR49","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/ana.26574","volume":"93","author":"M Shahid","year":"2023","unstructured":"Shahid, M. et al. Illusory Responses across the Lewy Body Disease Spectrum. Ann. Neurol. 93, 702\u2013714 (2023).","journal-title":"Ann. Neurol."},{"key":"1341_CR50","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WRLA Gibb","year":"1988","unstructured":"Gibb, W. R. L. A. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 51, 745\u2013752 (1988).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1341_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27, 349\u2013356 (2012).","journal-title":"Mov. Disord."},{"key":"1341_CR52","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith, I. G. et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 94, 743\u2013755 (2020).","journal-title":"Neurology."},{"key":"1341_CR53","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre, M. et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov. Disord. 22, 1689\u20131707 (2007).","journal-title":"Mov. Disord."},{"key":"1341_CR54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and managament of dementia with Lewy bodies. Neurology. 89, 88\u2013100 (2017).","journal-title":"Neurology."},{"key":"1341_CR55","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer's Dement 7, 263\u2013269 (2011).","journal-title":"Alzheimer's Dement"},{"key":"1341_CR56","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1341_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state. A practical method grading Cogn. state patients' clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"1341_CR58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/WAD.0000000000000111","volume":"30","author":"SE Monsell","year":"2016","unstructured":"Monsell, S. E. et al. Results from the NACC uniform data set neuropsychological battery crosswalk study. Alzheimer's Assoc. Disord. 30, 134\u2013139 (2016).","journal-title":"Alzheimer's Assoc. Disord."},{"key":"1341_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14442","volume":"21","author":"AN Trelle","year":"2025","unstructured":"Trelle, A. N. et al. Plasma Abeta(42)\/Abeta(40) is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer\u2019s disease spectrum. Alzheimer's Dement 21, e14442 (2025).","journal-title":"Alzheimer's Dement"},{"key":"1341_CR60","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-022-01116-2","volume":"14","author":"EN Wilson","year":"2022","unstructured":"Wilson, E. N. et al. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer\u2019s disease. Alzheimers Res. Ther. 14, 172 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1341_CR61","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1007\/s00415-023-11810-2","volume":"270","author":"JS Middleton","year":"2023","unstructured":"Middleton, J. S. et al. Seed amplification assay results illustrate discrepancy in Parkinson\u2019s disease clinical diagnostic accuracy and error rates. J. Neurol. 270, 5813\u20135818 (2023).","journal-title":"J. Neurol."},{"key":"1341_CR62","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/acn3.52034","volume":"11","author":"MJ Plastini","year":"2024","unstructured":"Plastini, M. J. et al. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer\u2019s disease spectra. Ann. Clin. Transl. Neurol. 11, 1197\u20131210 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1341_CR63","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/brain\/awaa021","volume":"143","author":"EN Wilson","year":"2020","unstructured":"Wilson, E. N. et al. Soluble TREM2 is elevated in Parkinson\u2019s disease subgroups with increased CSF tau. Brain 143, 932\u2013943 (2020).","journal-title":"Brain"},{"key":"1341_CR64","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea, D. et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann. Clin. Transl. Neurol. 6, 1815\u20131824 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1341_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae458","volume":"7","author":"JR Winer","year":"2024","unstructured":"Winer, J. R. et al. 18F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease. Brain Commun. 7, fcae458 (2024).","journal-title":"Brain Commun."},{"key":"1341_CR66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse, S. K. et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 13, 99 (2021).","journal-title":"Alzheimers Res Ther."},{"key":"1341_CR67","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1212\/WNL.0000000000000154","volume":"82","author":"G Kerchner","year":"2014","unstructured":"Kerchner, G. et al. APOE \u03b54 worsens hippocampal CA1 apical neuropil atrophy and episodic memory. Neurology 82, 691\u2013697 (2014).","journal-title":"Neurology"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01341-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01341-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01341-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:41:39Z","timestamp":1782891699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01341-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01341-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These authors declare competing interests: LMG has received speaker fees from Quanterix and Esteve and served as a consultant for Quanterix. MJP is currently a full-time employee at Amprion Inc. DA has participated in advisory boards for Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. DA holds a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx NeuroSciences N.V., WO2019175379 Markers of synaptopathy in neurodegenerative diseases). JF has served on advisory boards, adjudication committees, or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Novo Nordisk, Perha, Roche, Zambon, Spanish Neurological Society, T21 Research Society, Lumind Foundation, J\u00e9r\u00f4me-Lejeune Foundation, Alzheimer\u2019s Association, National Institutes of Health USA, and Instituto de Salud Carlos III. JF also holds a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx NeuroSciences N.V., WO2019175379 Markers of synaptopathy in neurodegenerative diseases). HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work). KLP has been on the Scientific Advisory Board for Amprion and has been a consultant for Novartis, Lilly, BioArctic, Biohaven, Curasen and Neuron23. CA has received honoraria as a speaker from Hoffman-La Roche LTD, Nutricia, Schwabe Farma Ib\u00e9rica SAU and Zambon; and is a member of the Board of Directors of the Lewy Body Dementia Association, the Scientific Committee of Lewy Body Espa\u00f1a, and the Alzheimer\u2019s Association International Society to Advance Alzheimer\u2019s Research and Treatment (ISTAART) Advisory Council. All other authors (AMS, SAL, BA, NJA, ENW, IRB, CBY, JRW, MSB, HV, TP, EVC, IS, JHM, VR, GAK, KIA, VWH, TJM, LT, and ECM) declare no financial or non-financial competing interests. No authors have pending patent applications related to the work described in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}